英文名称 |
中文名称 |
CAS号 |
操作 |
Tofacitinib Impurity 22 TF103-K |
托法替尼杂质22 TF103-K |
2227199-28-0 |
详细
|
Norepinephrine impurity D hydrochloride |
去甲肾上腺素杂质D 盐酸盐 |
66403-32-5 |
详细
|
Z-Valaciclovir |
Z-伐昔洛韦 |
124832-31-1 |
详细
|
3-(hexyloxy)-4-(pyridin-3-yl)-1,2,5-thiadiazole |
3-(4-已氧基-1,2,5 -噻二唑-3-基)吡啶 |
131987-69-4 |
详细
|
2-Chloro-N-(4-methylphenyl)propanamide |
2-氯-N-(4-甲基苯基)丙酰胺 |
147372-41-6 |
详细
|
Doltenolil control |
多替诺雷对照品 |
1285572-51-1 |
详细
|
1-Methoxy-3-(trimethylsilyloxy)-1,3-butadiene |
1-甲氧基-3-三甲基硅氧基-1,3-丁二烯 |
59414-23-2 |
详细
|
Dotinurad Impurity 3 |
多替诺雷杂质3 |
29568-76-1 |
详细
|
Flurbiprofen Impurity d(4-ACB) |
氟比洛芬杂质d(4-ACB) |
477860-13-2 |
详细
|
3-hydroxy-4H-pyran-4-one |
3-羟基-4氢-吡喃-4-酮 |
496-63-9 |
详细
|
Urapidil Impurity (w-4-2) |
乌拉地尔杂质(w-4-2) |
793672-13-6 |
详细
|
2-(Propamino)-N-(o-toluene)acetamide |
2-(丙氨基)-N-(邻甲苯基)乙酰胺 |
145133-92-2 |
详细
|
FTD-17 epimer |
FTD-17位差向异构体 |
140375-21-9 |
详细
|
Bempedoic acid Impurity 17 |
贝派地酸杂质17 |
2570179-40-5 |
详细
|
Dotinurad Impurity 2 |
多替诺雷杂质2 |
137-07-5 |
详细
|
Lornoxicam impurity SM3-2 |
氯诺昔康杂质SM3-2 |
6482-26-4 |
详细
|
N-(o-tolyl)propionamide |
N-(邻甲苯基)丙酰胺 |
19343-15-8 |
详细
|
1,1-Dimethylethyl 2,4,6-trideoxy-3,5-O-(1-methylethylidene)-6-[(5-methyl-1,3,4-thiadiazol-2-yl)sulfonyl]-D-erythroheconate |
1,1-二甲基乙基 2,4,6-三脱氧基-3,5-O-(1-甲基亚乙基)-6-[(5-甲基-1,3,4-噻二唑-2-基)磺酰基]-D-赤己糖酸盐 |
1326302-97-9 |
详细
|
Linagliptin impurity E trifluoroacetate |
利格列汀杂质E 三氟乙酸盐 |
|
详细
|
Propyl benzylcarbamate |
苄基氨基甲酸丙酯 |
|
详细
|
Cefazolin Ep Impuirty L |
头孢唑林 EP 杂质 L |
|
详细
|
Chlorphenamine EP Impurity D |
氯苯那敏 EP杂质D |
65676-21-3 |
详细
|
|
美阿沙坦钾杂质 |
3031851-96-1 |
详细
|
GLT-Q |
|
|
详细
|
E-2-5 |
E-2-5 |
|
详细
|
|
(1R,5S,6S)-3-乙基螺环[双环[3.2.0]庚-3-烯-6,3’吡咯烷]-5’-酮 |
3042853-06-2 |
详细
|
|
[(1R,5S,6S)-6-(氨甲基)-3-乙基双环[3.2.0]庚-3-烯-6基]乙酸叔丁酯扁桃酸盐 |
|
详细
|
LeterMovir Impurity INT3-F |
莱特莫韦杂质INT3-F |
2864441-31-4 |
详细
|
E-2-3 |
|
|
详细
|
E-1-4 |
E-1-4 |
83121-15-7 |
详细
|
|
硫酸艾莎康唑杂质A |
2732924-99-9 |
详细
|
|
硫酸艾莎康唑杂质C |
2962831-01-0 |
详细
|
Fluthioxetine hydrobromide impurity 10 |
氢溴酸氟硫西汀杂质10 |
|
详细
|
Azilsartan Impurity E |
美阿沙坦钾杂质E |
1565796-93-1 |
详细
|
2,6-diaminophenol |
2,6-二氨基苯酚 |
22440-82-0 |
详细
|
(R)-N-Benzyl-2-(3-Benzylureido)-3-Methoxypropanamide |
(R) -N-苄基-2-(3-苄基脲基)-3-甲氧基丙酰胺 |
2295925-90-3 |
详细
|
Stiripentol Impurity 4 |
司替戊醇杂质4 |
106175-03-5 |
详细
|
Cefazolin Impurity N |
头孢唑林钠杂质 N |
2384108-14-7 |
详细
|
Sulfuric acid, bis(2-Methylpropyl) ester |
硫酸双(2-甲基丙基)酯 |
23304-40-7 |
详细
|
MD102-Z2 |
|
35139-68-5 |
详细
|
YD-SM201 |
|
7463-53-8 |
详细
|
Cefazolin USP Impurity A |
头孢唑林USP杂质A |
21732-17-2 |
详细
|
Cefazolin Impurity B |
头孢唑林杂质B |
1675245-47-2 |
详细
|
Cefazolin Impurity H |
头孢唑林杂质H |
56842-77-4 |
详细
|
Cefazolin Impurity J |
头孢唑林杂质J |
32510-61-5 |
详细
|
Cefazolin Impurity L |
头孢唑林杂质L |
1675244-99-1 |
详细
|
Impurity 14 |
杂质14 |
1252018-10-2 |
详细
|
Demethylparool |
去甲基帕罗醇 |
220548-73-2 |
详细
|
1-(2-Chlorophenyl)-2-(1-tetrazolyl)ethanone |
1-(2-氯苯基)-2-(1-四唑基)乙酮 |
1259059-68-1 |
详细
|
E-2-1 |
|
118452-04-3 |
详细
|
Mirabelon intermediates 4 |
米拉贝隆中间体4 |
223673-36-7 |
详细
|
Escitalopram oxalate impurity 05 |
草酸艾司西酞普兰杂质05 |
762266-07-9 |
详细
|
Escitalopram oxalate impurity 01 |
草酸艾司西酞普兰杂质01 |
762266-09-1 |
详细
|
Escitalopram oxalate impurity 03 |
草酸艾司西酞普兰杂质03 |
1433278-32-0 |
详细
|
AZD9291 chloropropylamide |
AZD9291氯丙酰胺 |
1421373-36-5 |
详细
|
1C in benzethazine impurities |
苄丝肼杂质中1C |
5625-41-2 |
详细
|
Fenofibrate impurity H |
非诺贝特杂质H |
2991460-92-3 |
详细
|
BBXS-B |
|
14737-89-4 |
详细
|
Valsartan Impurity INT1-C (Valsartan Impurity E) |
缬沙坦杂质INT1-C(缬沙坦杂质E) |
443093-86-5 |
详细
|
VAL impurity INT1-B |
VAL杂质INT1-B |
1189547-11-2 |
详细
|
Roxadustat impurity IV-7 control |
罗沙司他杂质IV-7对照品 |
|
详细
|
6-[5-Amino-3-(4-phenoxy-phenyl)-4,5-dihydro-1H-pyrazole-4-yl]-3-(4-phenoxy-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine |
6-[5-氨基-3-(4-苯氧基-苯基)-4,5-二氢-1H-吡唑-4-基]-3-(4-苯氧基-苯基)-1H-吡唑并[3,4-d]嘧啶-4-胺 |
|
详细
|
Vonoprazan Impurity 102 |
沃诺拉赞杂质102 |
403-29-2 |
详细
|
Anthenioxysulfuryl chloride |
茴二氧基硫酰氯 |
105764-39-4 |
详细
|
6-(6-Aminohexanamido)hexanoic acid |
6-[(6-氨基-1-氧代己基)氨基]-己酸 |
2014-58-6 |
详细
|
Atorvastatin Related Compound C |
阿托伐他汀钙杂质C |
693793-53-2 |
详细
|
Atorvastatin Related Compound D |
阿托伐他汀钙杂质D |
148146-51-4 |
详细
|
Impurity H |
杂质h |
125995-03-1 |
详细
|
Escitalopram oxalate impurity 04 |
草酸艾司西酞普兰杂质04 |
260371-16-2 |
详细
|
Finerenone P5-2 |
非奈利酮P5-2 |
65582-57-2 |
详细
|
Finerenone RJ |
非奈利酮RJ |
3046142-41-7 |
详细
|
Finerenone RE |
非奈利酮RE |
3046141-72-1 |
详细
|
3-(1,2,5-thiosadiazepine-3-yl)pyridine |
3-(1,2,5-硫杂二氮杂环戊熳-3-基)吡啶 |
131987-88-7 |
详细
|
Fenofibrate impurity J |
非诺贝特杂质J |
388632-17-5 |
详细
|
N-Nitroso Paroxetine |
N-硝基帕罗西汀 |
2361294-43-9 |
详细
|
TL-Z2 |
|
69240-90-0 |
详细
|
Triazine ring impurities |
三嗪环杂质 |
68984-32-7 |
详细
|
hydride |
氢化物 |
76820-35-4 |
详细
|
Vitamin A palmitate oxidized Impurity |
维生素A棕榈酸酯氧化杂质 |
3012-64-4 |
详细
|
Cefazolin Impurity N |
头孢唑林杂质N |
|
详细
|
E-2-2 |
|
|
详细
|
Cefazolin Impurity M |
头孢唑林杂质M |
|
详细
|
|
5-[4-(己基氧基)-1,2,5-硫杂二氮杂环戊熳-3-基]-3-羟基-1-甲基吡啶-1-正离子 |
2414049-88-8 |
详细
|
3-Azetidinecarboxylic acid, 1-[[4-[(1Z)-1-[[[4-cyclohexyl-3-(trifluoromethyl)phenyl]methoxy]imino]ethyl]-2-ethylphenyl]methyl]- |
|
2768181-14-0 |
详细
|
4-amino-1,3-dihydro-2H-benzo[d]imidazole-2-thione |
4-氨基-1,3-二氢-2H-苯并[d]咪唑-2-硫酮 |
19462-97-6 |
详细
|
Impurity BLPN-Z2 |
杂质 BLPN-Z2 |
|
详细
|
Ruxolitinib SM2-G |
芦可替尼SM2-G |
|
详细
|
SHJJBBTS-D |
SHJJBBTS-C |
918641-99-3 |
详细
|
SHJJBBTS-D |
|
71433-06-2 |
详细
|
Fenofibrate impurity Ⅱ-5 |
非诺贝特杂质Ⅱ-5 |
31702-79-1 |
详细
|
|
[(1S,5R,6S)-6-(氨甲基)-3-乙基双环[3.2.0]庚-2-烯-6基]乙酸 |
1234045-56-7 |
详细
|
2-Hydroxy-2-(pyridin-3-yl)acetic acid |
2-羟基-2-(吡啶-3-基)乙酸 |
49769-60-0 |
详细
|
Finerenone RG |
非奈利酮RG |
|
详细
|
Ruxolitinib INT3-A |
芦可替尼INT3-A |
|
详细
|
Finerenone P1-4-Z |
非奈利酮P1-4-Z |
|
详细
|
|
[(1R,3E,5R,6S)-6-(氨甲基)-3-亚乙基双环[3.2.0]庚-3-烯-6基]乙酸 |
1644251-71-7 |
详细
|
Amoxetine HA1405-Impurity 1 |
阿姆西汀HA1405-杂质1 |
|
详细
|
Finerenone P1-5 |
非奈利酮P1-5 |
|
详细
|
2-Hydroxy-3',4'-dihydroxyacetophenone |
3,4-二羟基苯酰甲醇 |
29477-54-1 |
详细
|
1,2-Bis(4-phenylbutyrate)-3-hydroxypropanediester |
1,2-双( 4-苯丁酸) -3-羟基丙二酯 |
1443417-10-4 |
详细
|